InStrong

InStrong is a thermostable recombinant insulin biologic being developed by Lamark Biotech for the treatment of insulin-dependent diabetes. Utilizing protein engineering, InStrong is designed to remain stable at room temperature or higher, potentially eliminating the need for cold-chain storage and transport, which is a significant barrier to insulin access in many regions. The program includes specific candidates such as INS-RTA and INS-R2T, which are currently in IND-enabling studies. As a protein-engineered biologic, it aims to provide the same glucose-lowering effects as traditional insulin but with enhanced physical stability.

Brand names

InStrong